Finder

Current NHS consultant posts held

I no longer work as an NHS consultant but I continue to consult at the private wings of both Charing Cross and Hammersmith Hospitals.

Research interests

Published over 300 papers on the biology and treatment of human cancer for over 40 years.
In recent focus has been on the management of breast cancer currently on the the value of molecular profiling of advanced cancer to better select effective drug therapy.
Set up the Anglo Celtic Collaborative Oncology Group- trials in breast cancer continue.

Personal interests

Help set up Maggies Cancer Caring Charity with my patient, Maggie Jencks and research nurse , Laura Lee who is now Chief Executive
Now over 15 centres at major Cancer Centre sites in UK and abroad
Main Board Medical Member and Chair Professional Advisory Board
Ex-Chair Research Committee 'Breast Cancer Care'
Continue sporting activity in football, golf.
Amateur astronomy, cosmology
Classical Music

Awards received

Medical School Final Year Prizes in Medicine, surgery, pathology and clinical medal.
Postgraduate research prize in Oxford
Cancer Research Campaign Traveliing Fellow to Dana Farber Cancer Centre, Boston 1981-2
Team leader and Finalist in Hospital Doctor of the Year Oncology 1994
Finalist Communication in Oncology 1995
2005 Special Commendation Hospital Doctor of the Year-Oncology Team

Publications

A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN.
Leonard RC, et al Anglo-Celtic Collaborative Oncology Group. Ann Oncol. 2015 Sep 28.
Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP,
Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander
AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP,
Pedrazzoli P, Bregni M, Demirer T. High-dose chemotherapy with autologous
stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized
trials. J Clin Oncol. 2011 Aug 20;29(24):3214-23
Mansi JL, Yellowlees A, Lipscombe J, Earl HM, Cameron DA, Coleman RE, Perren T,
Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Evans TR.
Five-year outcome for women randomised in a phase III trial comparing doxorubicin
and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in
early breast cancer: an Anglo-Celtic Cooperative Oncology Group study. Breast Cancer Res Treat. 2010 Aug;122(3):787-94.
Malinovszky KM, Gould A, Foster E, Cameron D, Humphreys A, Crown J, Leonard RC; Anglo Celtic Co-operative Oncology Group. Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer. Br J Cancer. 2006 Dec 18;95(12):1626-31
Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ; NEAT Investigators and the SCTBG. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006 Nov 2;355(18):1851-62.
Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann

Courses offered to GPs

Many seminars in UK and internationally on breast cancer; importance of dose intensity for adjuvant chemotherapy
Recently- molecular profiling for advanced cancer management